USPTO serial 87172058
CSL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 24, 2018
- Examiner
- NEHMER, JASON ROBERT
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 704 applies to Madrid Protocol extensions of protection in the U.S. Section 71 (similar to Section 8) showing continued use was accepted. The U.S. extension remains active. Follow Madrid and USPTO deadlines for the next renewal cycle.
Need help with CSL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Parkville, Victoria, AU
Parkville, Victoria, AU
Parkville, Victoria, AU
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott D. Woldow
Scott D. Woldow Smith, Gambrell & Russell, LLP1055 Thomas Jefferson Street, NWSuite 400Washington, DC 20007Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Chemical and biological reagents for non-medical purposes; chemical and biological reagents for industrial use for anti-body screening, blood grouping, and for the typing and detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant compliment components and immunoglobulin subtypes; cell cultures and media, namely, biological preparations for use in cell cultures other than for medical and veterinary use; cell growth media for growing cells for use in scientific research; cell media for growing cells for use in scientific research, namely, for use in the production of pharmaceuticals, vaccines, monoclonal antibodies and recombinant proteins; chemical test kits for the detection of specific blood cells, determining the presence of antigens on blood cells, and the detection of relevant compliment compounds and immunoglobulin subtypes for laboratory or research use; chemical preparations for scientific purposes and for use in industry; chemical preparations, namely, diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology in the nature of reagents for use in the preparation of invitro diagnostic kits; chemical preparations, namely, monoclonal antibodies for use in invitro scientific or research use; chemical preparations for industrial use for anti-body screening, blood grouping, and the typing and detection of specific blood cells; diagnostic and testing agents for scientific or research use, namely, reagents for use in anti-body screening, blood grouping and the typing and detecting of specific blood cells; diagnostic reagents and preparations except for medical or veterinary use ] | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical preparations and substances for the treatment and/or prevention of blood or bleeding disorders, influenza, respiratory disease and disorders; pharmaceutical preparations and substances for the treatment and/or prevention of stroke or heart failure; vaccines; anti-virals; antigens for medical purposes; blood products in this class, namely, blood plasma, reagent blood cells; products derived from blood and products derived from recombinant DNA technology, namely, immunoglobulins, human albumin, blood clotting factors, plasma volume expanders, blood proteins for therapeutic use; serums, namely, anti-venoms; medicated serums for the treatment of blood or bleeding disorders; [ test kits in the class, namely, invitro diagnostic reagent test kits for use in detecting cell mediated immune response; pharmaceutical preparations and substances, namely, RhD reagents for the detection of specific antigens or in blood typing; pharmaceutical preparations, namely, reagent red blood cells used to detect antibodies or IgG subtypes; pharmaceutical preparations, namely, monoclonal and polyclonal antibodies; pharmaceutical preparations, namely, reagents for medical/clinical use for the typing and detection of specific blood cells, and the detection of relevant compliment components and immunoglobulin subtypes ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 16, 2025 | NAS8 | NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED | — |
| Jun 16, 2025 | 8.PR | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED | — |
| Mar 13, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jul 19, 2024 | ES8R | TEAS SECTION 8 RECEIVED | — |
| Jul 24, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 11, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 11, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 11, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 11, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 11, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 11, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 17, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 17, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 24, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 15, 2018 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Jun 15, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 18, 2018 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| May 18, 2018 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Nov 21, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 17, 2017 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 17, 2017 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 17, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 23, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 28, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 28, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 8, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 22, 2017 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 13, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 9, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 9, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 2, 2017 | ALIE | ASSIGNED TO LIE | — |
| Jan 17, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 27, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 27, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 27, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 20, 2016 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 19, 2016 | NWAP | NEW APPLICATION ENTERED | — |